Skip to main content

AlphaGenome 2: DeepMind’s new AI model maps genetic variants to individual cell types

AlphaGenome 2: DeepMind’s new AI model maps genetic variants to individual cell types

THE TECH CHRONICLE  ·  technology  ·  Thursday, November 12, 2026
AlphaGenome 2: DeepMind’s new AI model maps genetic variants to individual cell types

The model is positioned as a finer‑grained successor to the original AlphaGenome, extending the resolution at which genetic effec…

By TechPulse Blog

Google DeepMind announced the launch of AlphaGenome 2, an AI‑driven predictive engine for human genetics that forecasts how specific genetic variants influence distinct cell types and cellular states. The model is positioned as a finer‑grained successor to the original AlphaGenome, extending the resolution at which genetic effects can be interpreted.

Key Takeaways

  • AlphaGenome 2 predicts the impact of genetic variants on individual cell types and states.
  • The system is described as a “predictive engine for human genetics” offering higher granularity than its predecessor.
  • Researchers stress that cell‑type specificity is crucial for advancing drug development.
  • Google DeepMind’s AI‑for‑science leadership includes Adam Gayoso, Žiga Avsec and Pushmeet Kohli.
  • Further scientific results are expected to follow the announcement.
Metric Value Why it matters
Model name AlphaGenome 2 Enables fine‑grained prediction of variant effects across cell types.
Developed by Google DeepMind Leverages DeepMind’s AI expertise for biomedical research.
Key researchers Adam Gayoso, Žiga Avsec, Pushmeet Kohli Provide scientific and technical leadership for the project.

What AlphaGenome 2 Does

AlphaGenome 2 functions as a computational engine that evaluates how individual genetic variants alter the behavior of specific cell types and their transient states. By moving beyond bulk‑tissue analyses, the model delivers predictions at the resolution of single‑cell contexts, which is essential for interpreting the functional consequences of rare or non‑coding variants.

Technical Distinction from the Original AlphaGenome

The original AlphaGenome provided a broad overview of variant effects across tissues. AlphaGenome 2 refines this approach, delivering cell‑type and state‑specific insights that were previously unattainable. This increased granularity is framed by DeepMind as a “predictive engine for human genetics,” underscoring the shift from population‑level inference to cellular precision.

Insights from the Research Team

“tying human genetics to cell biology.” – Adam Gayoso, research scientist, Google DeepMind

Adam Gayoso highlighted the model’s role in bridging genetic variation with cellular mechanisms. Žiga Avsec, the genomics lead, emphasized that cell‑type specificity is a prerequisite for rational drug discovery, noting that therapeutic targets often manifest only in particular cellular environments. Pushmeet Kohli, head of DeepMind’s AI‑for‑science division, indicated that AlphaGenome 2 is part of a broader pipeline of scientific outputs that DeepMind plans to release.

Implications for Drug Development

By pinpointing the cellular contexts in which a variant exerts its effect, AlphaGenome 2 offers a roadmap for identifying druggable pathways that are active only in disease‑relevant cell states. This precision could streamline target validation, reduce off‑target risks, and accelerate the translation of genomic findings into therapeutic candidates.

Future Directions

The announcement signals the beginning of a series of scientific releases from DeepMind’s AI‑for‑science program. While AlphaGenome 2 marks a substantial step forward, the team anticipates further refinements, integration with larger multi‑omics datasets, and expanded validation across diverse disease models.

Why it matters

AlphaGenome 2 illustrates how advanced AI can translate raw genomic data into actionable, cell‑level insights, a capability that has been a bottleneck in precision medicine. Its focus on individual cell types aligns with emerging therapeutic strategies that aim to modulate disease pathways with minimal systemic impact. As the model matures, it may become a foundational tool for researchers seeking to connect genotype to phenotype with unprecedented specificity.

Frequently asked questions

Who developed AlphaGenome 2?

The model was created by Google DeepMind, the AI research division of Alphabet.

What does AlphaGenome 2 predict?

It forecasts how specific genetic variants influence the function and state of individual cell types.

How does AlphaGenome 2 differ from the original AlphaGenome?

AlphaGenome 2 offers a finer‑grained, cell‑type and state‑specific view, whereas the original model provided broader tissue‑level predictions.

Which researchers commented on the model’s significance?

Adam Gayoso described it as “tying human genetics to cell biology,” Žiga Avsec discussed its relevance for drug development, and Pushmeet Kohli hinted at additional scientific results.

What are the next steps for AlphaGenome 2?

DeepMind plans to release further scientific findings, expand the model’s integration with other datasets, and validate its predictions across more disease contexts.

Bottom Line

AlphaGenome 2 represents a notable advance in AI‑driven genomics by delivering cell‑type specific predictions of variant effects, a capability that could accelerate drug discovery and deepen our understanding of disease mechanisms.

The model’s release marks the start of a broader rollout of DeepMind’s AI‑for‑science tools, positioning the company at the forefront of computational biology.

Reporting based on: original source.

Comments

Popular posts from this blog

Tracking your plastic: Exposing recycling myths

Tracking your plastic: Exposing recycling myths Marketplace journalists go undercover overseas and pose as recycling brokers to expose the lucrative plastic recycling business. We reveal that Malaysian companies are willing to break the law to buy Canadian plastic and show how some of it is dumped and burned in illegal landfills, where the toxic fumes and run-off appear to be making people sick. Back in Canada, we buy nine tonnes of plastic and secretly track where big companies are taking it. Will it actually get recycled? »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS Connect with CBC News Online: For breaking news, video, audio and in-depth coverage: http://bit.ly/1Z0m6iX Find CBC News on Facebook: http://bit.ly/1WjG36m Follow CBC News on Twitter: http://bit.ly/1sA5P9H For breaking news on Twitter: http://bit.ly/1WjDyks Follow CBC News on Instagram: http://bit.ly/1Z0iE7O Download the CBC News app for iOS: http://apple.co/25mpsUz Download the CBC News app for ...

Red states now legalizing recreational marijuana too

Red states now legalizing recreational marijuana too The 2020 election proved how broadly accepted recreational marijuana has become throughout the US and across party lines, with measures to legalize recreational pot breezing to victories in Arizona, New Jersey, Montana and South Dakota. (Nov. 12) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/2ImtqJ5

Two virus survivors get double lung transplants

Two virus survivors get double lung transplants A young paralegal and a car mechanic received lifesaving double lung transplants at Northwestern Medicine in Chicago after COVID-19 destroyed their lungs. (July 30) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/310Ng1O